Muscarinic and Nicotinic Receptors in Alzheimer's Disease: Rationale for Cholinergic Drug Treatment

PA Lapchak, DM Araujo, R Quirion - Novel Approaches to the Treatment of …, 1989 - Springer
Alzheimer's disease (AD) is characterized by an extensive degeneration of the cholinergic
system in the human nucleus basalis of Meynert, neocortex and hippocampus (1–5), mainly …
被引用次数：2 相关文章
[PDF] ethernet.edu.et

[PDF][PDF] MUSCARINIC AND NICOTINIC RECEPTORS IN ALZHEIMER'S DISEASE: RATIONALE FOR CHOLINERGIC DRUG TREATMENT

PA Lapchak, DM Araujo, R Quirion - Novel Approaches to the … - ndl.ethernet.edu.et
Neuroanatomy Lab., Montreal Neurological Inst. 3801 University St., Montreal, Quebec, H3A
2B4 and Douglas Hospital Res. Ctr., 6875 Lasalle Blvd Verdun, Quebec, H4H lR3 …

MUSCARINIC AND NICOTINIC RECEPTORS IN ALZHEIMER'S DISEASE: RATIONALE FOR CHOLINERGIC DRUG TREATMENT

PA Lapchak, DM Araujo, R Quirion - Novel Approaches to the …, 2013 - books.google.com
Alzheimer's disease (AD) is characterized by an extensive degeneration of the cholinergic
system in the human nucleus basalis of Meynert, neocortex and hippocampus (1-5), mainly …
[PDF] ethernet.edu.et

[PDF][PDF] MUSCARINIC AND NICOTINIC RECEPTORS IN ALZHEIMER'S DISEASE: RATIONALE FOR CHOLINERGIC DRUG TREATMENT

PA Lapchak, DM Araujo, R Quirion - Novel Approaches to the … - ndl.ethernet.edu.et
Neuroanatomy Lab., Montreal Neurological Inst. 3801 University St., Montreal, Quebec, H3A
2B4 and Douglas Hospital Res. Ctr., 6875 Lasalle Blvd Verdun, Quebec, H4H lR3 …